In the Spotlight...
Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia
Size-dependent activation of CAR-T cells
Transcriptomic diversity in human medullary thymic epithelial cells
An anti-CTLA-4 heavy chain-only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile
Previous Digests
Targeting tumor defenses to enhance immunotherapy
August 10, 2022
In cancer immunotherapy, research is often focused on improving the immune attack against cancer. However, Kishton and Patel et al. recently turned their attention towards how cancer defends itself against immune attacks, and how these defense mechanisms could potentially...
PD-1-high TILs: a predictive biomarker for ICB in lung cancer
August 3, 2022
Despite the promise of immune checkpoint blockade (ICB) therapy in treating non-small cell lung cancer (NSCLC), the majority of patients do not respond and toxicity remains a major issue. Identifying biomarkers of ICB efficacy could direct treatment to responsive...
Enhancing ACT with o9R
July 27, 2022
Adoptive T cell therapy has come a long way in recent years, but it typically requires lymphodepleting pre-treatment, which can limit patient eligibility, and its efficacy is still limited in many patients. In recent efforts to improve ACT, particularly...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
Donate to support researchersAbout ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Lespinasse-Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Samuel (Sandy) Goldman
Paula Hochman
Shishir Pant
Elaine Yee Lin Chung
Nathan Suek
Margot O'Toole
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
